K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc

This phase 3 study tests a new targeted drug, azenosertib, against standard chemotherapy in about 420 women with a specific type of ovarian cancer that no longer responds to platinum-based chemo. The cancer must have high levels of a protein called cyclin E1. The goal is to see i…